![](https://savarapharma.com/wp-content/uploads/page-header-blue-ridges-m.jpg)
![](https://savarapharma.com/wp-content/uploads/page-header-blue-ridges-d.jpg)
Filing
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15 (d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported) July
5, 2005
ADVENTRX
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
(State
or
other jurisdiction of incorporation)
001-32157
(Commission
File Number)
|
84-1318182
(IRS
Employer Identification No.)
|
6725
Mesa Ridge Road, Suite 100
San
Diego, California 92121
(Address
of principal executive offices) (Zip Code)
(858)
552-0866
(Company’s
telephone number, including area code)
Item
8.01. Other Events.
On
July
5, 2005, the Company announced it has been added to the Russell Investment
Group’s new Russell Microcap™ Index.
The
press
release issued by the Company on July 5, 2005 with respect to this matter is
included with this report as an exhibit.
Item
9.01. Financial Statements and Exhibits.
(c) |
The
exhibit list required by this item is incorporated by reference to
the
Exhibit Index filed as part of this
report.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
ADVENTRX Pharmaceuticals, Inc. | ||
|
|
|
By: | /s/ Carrie E. Carlander | |
Name:
Carrie E. Carlander
|
||
Title: Chief Financial Officer, Vice President, Finance, and Treasurer | ||
July
5, 2005
|
EXHIBIT
INDEX
Exhibit
|
Description
|
99.1
|
Press
Release of the Company dated July 5, 2005.
|
Exhibit
99.1
ADVENTRX
JOINS THE NEW RUSSELL MICROCAP INDEX
SAN
DIEGO -
July 5,
2005 - ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) today
announced that it has been added to the Russell Investment Group’s new Russell
Microcap™
Index.
Russell’s final membership lists of reconstituted U.S. indexes are available at:
http://www.russell.com/us/indexes/us/membership.asp.
The
Russell Microcap Index is comprised of the smallest 1,000 securities in the
small-cap Russell 2000Ò Index
plus the next 1,000 companies, based on a ranking of all U.S. equities by market
capitalization. According to Russell, the Microcap Index was designed to offer
managers and other investors a comprehensive, unbiased barometer to compare
their performance against the genuine microcap marketplace of
stocks.
According
to Russell, their indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for both passive
and
active investment strategies. More than $2.5 trillion in assets currently are
benchmarked to them. Investment managers who oversee these funds purchase shares
of member stocks according to that company’s weighting in the particular
index.
Companies
added to the Russell Microcap Index were ranked as of May 31 by total market
capitalization and weighted based on free-float adjustment, an integral aspect
of Russell index methodology. Free-float adjustment means stocks are weighted
by
their available market capitalization, which is calculated by multiplying the
closing price by the available shares.
About
ADVENTRX
ADVENTRX
Pharmaceuticals is a biopharmaceutical research and development company focused
on introducing new technologies for anticancer and antiviral treatments that
improve the performance and safety of existing drugs, by addressing significant
problems such as drug metabolism, toxicity, bioavailability or resistance.
The
Company’s lead compound, CoFactor, is a biomodulator of 5-fluorouracil (5-FU), a
widely used cancer chemotherapy. CoFactor is currently being tested with 5-FU
in
a US-based Phase II and an EU-based Phase IIb clinical trial as a first line
treatment of metastatic colorectal cancer. In addition, CoFactor has received
clearance under a special protocol assessment from the US FDA to begin a Phase
III pivotal clinical trial for metastatic colorectal cancer. More information
can be found on the Company's Web site at www.adventrx.com.
About
Russell Investment Group
Russell,
a global leader in multi-manager investment services, provides investment
products and services in more than 39 countries. Russell manages more than
$135
billion in assets and advises clients worldwide representing $2.3 trillion.
Founded in 1936, Russell is a subsidiary of Northwestern Mutual and is
headquartered in Tacoma, Wash., with additional offices in New York, Toronto,
London, Paris, Singapore, Sydney, Auckland and Tokyo.
Forward
Looking Statement
This
press release contains forward-looking statements within the meaning of the
"safe harbor" provisions of the Private Securities Litigation Reform Act of
1995. Such statements are made based on management's current expectations and
beliefs. Actual results may vary from those currently anticipated based upon
a
number of factors, including uncertainties inherent in the drug development
process, the timing and success of clinical trials, the validity of research
results, and the receipt of necessary approvals from the U.S. Food and Drug
Administration (FDA) and other regulatory agencies. For a discussion of such
risks and uncertainties, which could cause actual results to differ from those
contained in the forward-looking statements, see “Risk Factors” in the Company’s
last quarterly report on Form 10-Q, as well as other reports that the Company
files from time to time with the Securities and Exchange Commission. All
forward-looking statements are qualified in their entirety by this cautionary
statement. The Company undertakes no obligation to release publicly any
revisions, which may be made to reflect events or circumstances after the date
hereof.
Contact:
ADVENTRX
Pharmaceuticals
Andrea
Lynn
858-552-0866
Investor
Contact:
Lippert
Heilshorn & Associates
Jody
Cain
(jcain@lhai.com)
Brandi
Floberg (bfloberg@lhai.com)
310-691-7100
#
#
#